Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...

UNITY Biotechnology (NASDAQ:UBX) stock fell 30% after the company's mid-stage trial for its diabetic macular edema treatment ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient populationUBX1325 was ...

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...

UBX] has announced top-line results from the Phase IIb ASPIRE clinical trial of intravitreal UBX1325 (foselutoclax) in ...

After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will ...

UNITY Biotechnology (UBX) announced topline results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic ...